-
NASA scan discovers new, 'once in a century' Moon crater
-
Where the US-China tariff row stands ahead of White House summit
-
Most stocks rise as Fed hikes and indicates drive to curb inflation
-
Indonesia cash-for-photos scheme turns animal hunters into protectors
-
UK-Sudanese author pens book to give children 'African history of Africa'
-
Argentine judge orders suspension of Falklands oil project
-
US Congress passes sweeping Russia sanctions bill
-
US Fed raises rates to tackle 'too high' inflation, irking Trump
-
US stocks fall, dollar gains after Fed lifts interest rates
-
Turkey releases 106 protesters, jails more LGBTQ activists
-
US Fed raises rates to tackle 'too high' inflation in move sure to rile Trump
-
Candidate for UN chief calls for AI regulation akin to nuclear weapons
-
US Fed raises rates to battle inflation in move likely to rile Trump
-
'We're losing control,' AI pioneer Yoshua Bengio tells AFP
-
US House faces test on sweeping Russia sanctions bill
-
IR-MED and Dice Technologies Announce collaboration to Evaluate and Advance Pressure-Injury Prevention Platform in Japan
-
British PM says to make 'difficult decisions' as inflation rises
-
Watts, Pitt, Cruz to light up Spain's top film festival
-
Global fuel price demos: a round-up
-
Toogood Gold's Table Mountain Sits in the Shadow of a Nevada Gold Rush
-
Leverate Launches MCP for Traders to Connect AI Assistants With Trading Platforms
-
MEXC July–August Security Report: 38.66M USDT in Risk Funds Intercepted, Futures Insurance Fund Hits 792M USDT
-
MEXC Launches $1M "Discover Your Wall Street DNA" Campaign to Help Traders Find Their Market Fit
-
Emporio Armani names Dario Vitale new creative director
-
Stocks edge higher ahead of US Fed rate call
-
EU to ban social media for under 13s, curb access until 15
-
BASIS.pro Expands On-Chain Infrastructure with XDC Network Partnership and Zypher DAO as Auto Earn Goes Live
-
Wildfires push endangered Sumatran elephants to brink: Indonesian NGO
-
Pickle-flavoured tart? AI inspires Japan's convenience stores
-
Bank of Japan set to raise rates under pressure from inflation, US
-
EU chief hosts Canada's Carney in push to 'deepen' alliance
-
EU chief to unveil social media, gaming curbs for under-15s
-
Meta chief pushes back on AI slowdown calls
-
'Resident Evil' film brings video game's ethos to the big screen
-
US Fed to deliver rate decision with markets betting on hike
-
GA-ASI Mojave First UAS To Complete Battlefield Short Field Ops
-
i-payout Expands U.S. Money Transmitter Licensing Footprint and Advances European EMI Strategy
-
Sanders, Bannon warn of AI dangers in rare US left-right alignment
-
US Senate crypto bill collapses amid partisan deadlock
-
Empty benches as schools reopen in Venezuela's quake-hit Guaira
-
OpenAI, Anthropic and Google are working to create an AI standards body
-
Tiny English village holds 'independence' vote over asylum seeker housing
-
Protesting shepherds, farmers clash with Romanian police
-
US Treasury chief says to meet Chinese counterpart at weekend
-
Foundation Lets Ledger Users Switch to Open Source Without Starting Over
-
BingX Evolves into a Multi-Asset Trading Platform, Connecting Users to Global Opportunities
-
EU to propose curbing social media, online games for under 15s
-
International Trading Institute Expands Professional Trader Development Beyond the Master’s in Trading
-
FX Junction Reaches 40,600 Members and 26 Million Trades
-
Lake Energy Secures $80 Million for U.S. Renewable Energy Expansion
'Geneva patient' the latest in long-term remission from HIV
A man dubbed the "Geneva patient" is the latest person with HIV to be declared in long-term remission -- however he did not receive a transplant with a virus-blocking gene mutation like previous cases, researchers said Thursday.
Five people have previously been considered "cured" of HIV: the Berlin, London, Duesseldorf, New York and City of Hope, California patients.
All had bone marrow transplants to treat serious cases of cancer, receiving stem cells from a donor with a mutation of the CCR5 gene. This mutation is known to block HIV from entering the body's cells.
In 2018, the Geneva patient similarly received a stem cell transplant to treat a particularly aggressive form of leukaemia.
But this time the transplant came from a donor who did not carry the CCR5 mutation, French and Swiss researchers told a press conference in the Australian city of Brisbane as part of an AIDS conference that begins at the weekend.
This means that the virus is still able to enter the patient's cells.
However, 20 months after the man stopped taking antiretroviral treatment -- which reduces the amount of HIV in the blood -- doctors at Geneva University Hospitals have not found a trace of the virus in his system, the researchers said.
While they cannot rule out that the man's HIV will return, the researchers said they consider him to be in long-term remission.
"What is happening to me is magnificent, magical," the Geneva patient said in a statement.
The patient, a white man who chose not to be named, was diagnosed with HIV in 1990.
He had been on antiretrovirals until November 2021, when his doctors advised him to stop taking the treatment after the bone marrow transplant.
- 'Promising' -
Two previous cases, known as the Boston patients, had also received normal or "wild type" stem cells during their transplants. But in both cases, HIV returned a few months after they stopped taking antiretrovirals.
Asier Saez-Cirion, a scientist at France's Pasteur Institute who presented the Geneva patient case in Brisbane, told AFP that if there was still no sign of the virus after 12 months "the probability that it will be undetectable in the future increases significantly".
There were a couple of possible explanations for why the Geneva patient remains HIV free, Saez-Cirion said.
"In this specific case, perhaps the transplant eliminated all the infected cells without the need for the famous mutation," he said.
"Or maybe his immunosuppressive treatment, which was required after the transplant, played a role."
Sharon Lewin, the president of the International AIDS Society holding the HIV science conference in Brisbane, said the case was "promising".
"But we learned from the Boston patients that even a single" particle of the virus can lead to HIV rebounding, she cautioned.
"This particular individual will need to be watched closely over the next months and years."
While these cases of long-term remission raise hopes that one day HIV can truly be cured, the brutal and risky bone marrow transplant procedure is not an option for the millions of people living with the virus around the world.
It is instead a last-ditch attempt to treat life-threatening cancer in people who also have HIV.
However, there are hopes that the remission cases could point towards new avenues of research, such as the potential role played by immunosuppressive treatments.
Saez-Cirion said the case had also encouraged the researchers to continue studying innate immune cells, which act as the first line of defence against various pathogens, and could help control the virus.
For his part, the Geneva patient said he was now "looking to the future".
H.Cho--CPN